Publiceringsdatum |
Källa |
Titel på artikel |
2 juni, 2021 |
Biospace |
Calliditas is Getting to the Heart of Berger’s Disease |
9 mars, 2021 |
Akademiska Sjukhuset |
Innovativ behandling av njurinflammation prisas |
2 februari, 2021 |
Scrip |
How Sweden’s Calliditas Built Up Its US Presence And Development Portfolio |
9 december, 2020 |
The Balancing Act, Lifetime |
Behind the Mystery: IgA Nephropathy |
18 november, 2020 |
Pharmaceutical Technology |
Calliditas takes control of Genkyotex: expanding the rare disease pipeline |
28 september, 2020 |
Scrip |
Calliditas Nominated at the 2020 Scrip Awards |
24 juni, 2020 |
Optimum Communications |
Q&A: Getting to know Renee Aguiar-Lucander |
18 juni, 2020 |
European Mediscience Awards |
Calliditas Shortlisted at the 2020 European Mediscience Awards |
5 juni, 2020 |
Labiotech |
Upsized Nasdaq IPO Yields Calliditas €80M to Commercialize Kidney Drug |
28 februari, 2019 |
Pharmaceutical Technology |
Rare Disease Day 2019: Calliditas’ Nefecon takes on orphan conditions |
16 oktober, 2018 |
Pharmaphorum |
Calliditas pushing on with kidney disease drug after IPO success |
11 oktober, 2018 |
Vantage |
Hope on the horizon for rare kidney disease |